← Back to Search

Tyrosine Kinase Inhibitor

Povorcitinib for Prurigo Nodularis (STOP-PN1 Trial)

Phase 3
Recruiting
Research Sponsored by Incyte Corporation
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
* Pruritus, defined as an average Itch NRS score ≥ 7 during the 7 days prior to Day 1/Baseline.
* Total of ≥ 20 pruriginous lesions on ≥ 2 different body regions (both legs, and/or both arms, and/or trunk) at Screening and Day 1/Baseline.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 52 weeks
Awards & highlights
Pivotal Trial

Summary

This trial aims to see if povorcitinib can help reduce itching and skin rashes in people with prurigo nodularis.

Who is the study for?
This trial is for adults aged 18-75 with Prurigo Nodularis, a skin condition causing itchy bumps. Participants must have had the condition and related itching for at least 3 months, with at least 20 lesions across two body areas. They should have tried other treatments without success or cannot use them due to intolerance or contraindications.
What is being tested?
The study tests Povorcitinib's effectiveness on reducing itchiness and skin lesions in Prurigo Nodularis patients compared to a placebo (a substance with no active drug). It aims to determine if Povorcitinib can improve symptoms better than an inactive treatment.
What are the potential side effects?
Possible side effects of Povorcitinib may include reactions at the medication application site, general discomforts like headaches or nausea, potential impacts on liver function, and increased susceptibility to infections.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have had severe itching for the past week.
Select...
I have 20 or more itchy spots on at least 2 different parts of my body.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 52 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 52 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Proportion of participants achieving Itch NRS4 and IGA-CPG-S-TS at Week 24
Secondary study objectives
Change from baseline in Dermatology Life Quality Index (DLQI) score at each postbaseline visit.
Change from baseline in EQ-5D-5L score at each postbaseline visit
Change from baseline in Itch NRS score at each postbaseline visit
+21 more

Awards & Highlights

Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.

Trial Design

3Treatment groups
Experimental Treatment
Placebo Group
Group I: Povorcitinib Dose 2Experimental Treatment1 Intervention
Povorcitinib at the protocol-defined dose.
Group II: Povorcitinib Dose 1Experimental Treatment1 Intervention
Povorcitinib at the protocol-defined dose.
Group III: PlaceboPlacebo Group1 Intervention
Placebo at the protocol-defined dose.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Povorcitinib
2024
Completed Phase 1
~170

Find a Location

Who is running the clinical trial?

Incyte CorporationLead Sponsor
388 Previous Clinical Trials
63,305 Total Patients Enrolled
4 Trials studying Prurigo Nodularis
680 Patients Enrolled for Prurigo Nodularis
Incyte Medical MonitorStudy DirectorIncyte Corporation
33 Previous Clinical Trials
11,723 Total Patients Enrolled
2 Trials studying Prurigo Nodularis
354 Patients Enrolled for Prurigo Nodularis
~220 spots leftby Oct 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top